In the EU, rare diseases that are also life-threatening or chronically debilitating with a low prevalence and a high level of complexity are defined as orphan diseases.
Biosimilar medicines are follow-on versions of original biological medicines.
HTA should be based on an in-depth interaction to discuss specific data required in order to deci
HTAs should be a flexible process used collaboratively. The use of HTA to make reimbursement dec
A disease is defined as rare in Europe when it affects less than 1 in 2,000 citizens (Orphan Drug